A Rare Case of Pediatric BRAF V600E‐Mutated Erdheim–Chester Disease With Isolated Central Nervous System Onset: Diagnosis, Treatment, and Efficacy Evaluation

The authors declare no conflicts of interest. Supplementary Figure 1: Histopathological and immunohistochemical features of intracranial lesion tissue. (A) Foamy histiocytes are seen (haematoxylin and eosin, original magnification×200). (B) Foamy histiocytes are positive for CD68 (×200). (C) Histiocytes are negative for CD1a (×200). (D) Histiocytes are negative for Langerin (×200). Suplementary Figure 2: 18F-FDG-PET/CT images at initial diagnosis. (A-C) PET/CT scan shows multiple metabolically active lesions in the bilateral cerebellar hemispheres, sellar region, and pineal region (green circles). (D-F) PET/CT scan demonstrates metabolically active abnormal bone lesions involving the bilateral pelvic bones, femurs, and multiple bones of the feet (green and blue circles). Supplementary Figure 3: 18F-FDG-PET/CT images after dabrafenib treatment. (A-C) PET/CT scan shows complete normalization of metabolic activity in the CNS lesions after 15 months of dabrafenib treatment. (D-F) PET/CT scan demonstrates metabolic normalization in the bone lesions after 15 months of dabrafenib treatment. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.